Position in NVS
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$2,632,896
-$422,104 QoQ
Shares Held
16,800
-16.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.44%
of 13F equity value
Holder Rank
#376
of 1,603 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. holds $30,306,066 across 7 Drug Manufacturers - General names. NVS ranks #5 (8.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
80,000 | $10,107,200 | |
| 2 | AZN |
Astrazeneca PLC
|
30,000 | $5,688,600 | |
| 3 | JNJ |
Johnson & Johnson
|
18,300 | $4,647,651 | |
| 4 | MRK |
Merck & Co., Inc.
|
31,173 | $4,005,730 | |
| 5 | NVS |
Novartis AG
This page
|
16,800 | $2,632,896 | |
| 6 | LLY |
ELI LILLY & Co
|
1,500 | $1,799,145 | |
| 7 | SNY |
Sanofi
|
33,400 | $1,424,844 |
All Filings in NVS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,632,896 | 16,800 | Shares | Defined | 2026-07-23 | |
| 2026-03-31 | $3,055,000 | 20,000 | Shares | Defined | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||